MICROPORE TECHNOLOGIES LTD

Financial Health Score: B-

On an A–F scale, a B- indicates a company that is fundamentally solvent and meeting its obligations, but with underlying weaknesses that require attention. Micropore Technologies Ltd is not in immediate distress: filings are current, net assets are positive, and cash reserves have been rebuilt. However, the balance sheet strength largely reflects external equity investment rather than retained trading profits, and accumulated losses continue to grow.

Key Vital Signs

1. Liquidity (the company’s pulse) - Current assets of £2.64m against current liabilities of £0.64m gives a current ratio of roughly 4.1:1. This is a healthy reading, suggesting the company can cover short-term obligations several times over. - Cash at bank rose from £40,725 in 2024 to £328,105 in 2025, a significant improvement after years of volatility.

2. Solvency (overall body condition) - Net assets are £1,786,186, up from £1,676,496 in 2024. The company has recovered from negative net assets in 2017, 2018 and 2021. - Equity shown in the accounts comprises £4.88m of share premium, offset by £3.19m of accumulated profit and loss losses and a small amount of share capital. This means the net asset position is supported by investor capital rather than retained earnings.

3. Capital structure (circulatory system) - Unsecured loans repayable after more than one year stand at £1,460,485, equivalent to about 82% of net assets. This is a moderate-to-heavy debt load for a small business. - During the year the company issued new shares for approximately £936,000, indicating continued reliance on external capital injections.

4. Asset quality (tissue health) - Fixed assets are dominated by intangibles (trademarks, licences and development costs) of £1.09m. These are valuable but harder to convert quickly into cash than plant or inventory. - Debtors total £1.68m, but include £0.50m owed by group undertakings and £0.77m of deferred tax asset. Trade debtors are £0.13m, meaning much of the debtor book is not from external customers.

5. Profitability (metabolic function) - The filed accounts do not include a profit and loss account, but the movement in reserves shows the profit and loss reserve worsened from (£2,367,591) to (£3,194,468), a deterioration of roughly £827,000. This suggests the business is trading at a loss. - Employee numbers fell slightly from 17 to 16, indicating a stable but small operational base.

6. Compliance (vital administrative sign) - Accounts and confirmation statement are up to date and not overdue. The accounts were prepared under the small companies regime and are unaudited.

Diagnosis

Micropore Technologies Ltd presents as a company in recovery rather than crisis. Its short-term vital signs are strong: it can pay its bills, it holds a comfortable cash buffer, and its net asset position is positive. The underlying condition, however, is one of operational loss-making. The balance sheet looks increasingly robust because shareholders have injected new capital, not because the core business is generating surplus cash from trading.

Key symptoms: - Dependence on external transfusion: Recent share issues have funded the balance sheet improvement; without continued investor support, accumulated losses could erode equity. - Intangible asset reliance: A large proportion of fixed assets are development costs and intellectual property, which carry impairment risk if commercialisation stalls. - Debtor composition: A material portion of debtors is intercompany or tax-related rather than cash from trade customers. - Debt servicing: £1.46m of long-term unsecured loans must be repaid or refinanced from future cash flows.

The accounts state that the directors believe the company is a going concern. On the available figures, there is no immediate threat to that status, but the margin of safety depends on continued capital support and successful conversion of technology into profitable sales.

Prognosis: Stable to cautiously optimistic. If the company can narrow its operating losses and convert debtors into cash, the current liquidity provides a platform for growth. If losses persist and no further equity is forthcoming, the long-term debt load could strain resources and weaken the balance sheet.

Recommendations

1. Prioritise operating profitability: Review pricing, costs and sales channels to reduce the annual drain on reserves. The goal is to fund operations from trading rather than share issues.
2. Strengthen cash collection: Focus on converting trade debtors into cash and monitor amounts owed by group companies to ensure they remain recoverable.
3. Manage the debt load: As cash permits, consider repaying or refinancing the £1.46m of long-term unsecured loans to reduce gearing.
4. Protect the cash buffer: Maintain several months of operating expenses in cash to absorb trading volatility.
5. Review intangible carrying values: Regularly assess development costs and intellectual property for impairment, especially if expected revenue streams are delayed.
6. Maintain filing discipline: Continue submitting accounts and confirmation statements on time to avoid penalties and preserve creditworthiness.